Welcome to our dedicated page for Vanda Pharma SEC filings (Ticker: VNDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vanda Pharmaceuticals Inc. filings document the company's operating results, commercial product disclosures, regulatory developments, and public-company governance. Form 8-K reports include quarterly and annual financial results, product-related events for NEREUS and BYSANTI, clinical and regulatory forward-looking language, and management communications about commercial strategy.
The company's proxy and governance filings cover director elections, board composition, executive compensation, equity awards, annual bonus and salary decisions, and related stockholder voting matters. Other current reports document board expansion, officer changes, compensatory arrangements, exhibits to press releases, and risk-oriented disclosures tied to Vanda's marketed products and development pipeline.
Vanda Pharmaceuticals Inc. director Mitchell Stephen Ray reported a charitable gift of 25,836 shares of Common Stock on a Form 4. The transaction used code "G" for a bona fide gift and carried a price of $0.00 per share, meaning no sale proceeds were received. After this donation to a charitable organization, Ray directly holds 71,246 shares of Vanda common stock. This is a non-market transaction and does not reflect open-market buying or selling activity.
State Street Corporation reported beneficial ownership of 3,015,562 shares (5.1%) of Vanda Pharmaceuticals as of 03/31/2026 on a Schedule 13G. The filing shows shared voting power of 2,935,448 shares and shared dispositive power of 3,015,562 shares, with holdings held on behalf of multiple State Street advisory entities.
Vanda Pharmaceuticals Inc. reported Q1 2026 revenue of $51.7 million, up slightly from $50.0 million a year earlier, driven mainly by stronger Fanapt and PONVORY sales. Net loss widened to $48.6 million from $29.5 million as selling, general and administrative expenses rose to $68.4 million and research and development remained high at $28.4 million.
Cash and cash equivalents were $54.0 million with a further $148.3 million in marketable securities, and management believes this liquidity plus product sales can fund operations for at least 12 months. HETLIOZ sales declined amid U.S. generic competition, while Fanapt prescriptions grew strongly. The company highlighted FDA approval of milsaperidone for bipolar I disorder and schizophrenia, U.S. launch of NEREUS for motion-induced vomiting, and acceptance of a BLA for imsidolimab in generalized pustular psoriasis with a PDUFA date of December 12, 2026.
Vanda Pharmaceuticals reported Q1 2026 net product sales of $51.7 million, a 3% increase from Q1 2025, driven by 26% Fanapt® sales growth to $29.6 million. HETLIOZ® sales fell to $15.9 million, while PONVORY® rose to $6.2 million.
The company posted a net loss of $48.6 million (diluted loss per share $0.82), wider than the prior-year loss, reflecting higher selling, general and administrative spending and investments in launches and pipeline programs. Cash, cash equivalents and marketable securities totaled $202.3 million as of March 31, 2026.
Vanda raised its full-year 2026 revenue guidance to $240–$290 million, including $10–$30 million expected from newly launched NEREUS™. The quarter also featured FDA approval of BYSANTI™ (milsaperidone) for bipolar I disorder and schizophrenia and FDA acceptance of a BLA for imsidolimab in Generalized Pustular Psoriasis with a PDUFA target action date of December 12, 2026.
BlackRock Portfolio Management LLC filed an amendment to a Schedule 13G/A reporting beneficial ownership of 2,508,488 shares of Vanda Pharmaceuticals Inc. Common Stock. The filing shows 2,206,827 shares with sole voting power and states this equals 4.2% of the class.
Vanda Pharmaceuticals director Duncan Charles Cliff received an equity award of 57,101 shares of common stock in the form of restricted stock units (RSUs). The grant carries no cash exercise price and is recorded as a direct ownership position.
The RSU award is time-based and will vest in four equal annual installments, with the first vesting date on April 22, 2027, provided Cliff continues to serve the company through each annual vesting date. After this grant, his reported direct holdings from this award total 57,101 shares.
Vanda Pharmaceuticals Inc. director Duncan Charles Cliff filed an initial statement of beneficial ownership on Form 3. This filing identifies him as a director of Vanda and provides a baseline disclosure of his equity position and reporting status, without showing any reportable transactions in the provided data.
Vanda Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on June 4, 2026. Proposals include electing three Class II directors through 2029, ratifying PricewaterhouseCoopers as auditor, an advisory vote on executive pay and increasing shares under the 2016 Equity Incentive Plan.
The record date is April 17, 2026, with 60,135,062 common shares outstanding. The proxy highlights 2025 total revenue of $216.1 million, including Fanapt, HETLIOZ and PONVORY sales, year-end cash and securities of $263.8 million and a net loss of $220.5 million after a large non-cash tax valuation allowance. It also outlines multiple late-stage clinical programs, an FDA approval for tradipitant in motion sickness and a BLA filing for imsidolimab in generalized pustular psoriasis.